U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C8H14N4O2
Molecular Weight 198.2224
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TEMGICOLURIL

SMILES

CN1[C@H]2[C@H](N(C)C(=O)N2C)N(C)C1=O

InChI

InChIKey=XIUUSFJTJXFNGH-OLQVQODUSA-N
InChI=1S/C8H14N4O2/c1-9-5-6(11(3)7(9)13)12(4)8(14)10(5)2/h5-6H,1-4H3/t5-,6+

HIDE SMILES / InChI

Molecular Formula C8H14N4O2
Molecular Weight 198.2224
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Tetramethylglycoluril (MEBICAR, Adaptol, Mebicarum) is an anxiolytic similar to organism natural metabolites with nootropic and stress-protective characteristics. Tetramethylglycoluril belongs to a group of non-benzodizepam tranquilizers. It works by effecting on the structure of limbic-reticular activity and 4 main neuromediator systems – γ aminobutyric acid, choline -, serotonin- and adrenergic. Tetramethylglycoluril increases serotonin levels, decreases noradrenaline level with no effect on dopamine and no anticholinergic activity. It acts on hypothalamus emotional zone, thus providing moderate tranquilizing effect. Tetramethylglycoluril improves oxygen consumption by myocardium, normalizes blood electrolyte balance, stimulates protein synthesis and increases cell's energy resource. Tetramethylglycoluril is used to treat neurotic disorders (anxiety, awareness, fear, emotional density, irritability) caused by exhausting psycho-emotional, nervous and physical loads. Mebicar relieves or completely removes nicotine abstinence.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Adaptol
Primary
Adaptol

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
500 mg 2-3 times a day. The maximum single dose is 3 g, the daily - 10 g. The duration of the course of treatment is from several days to 2-3 months. In complex therapy as a means of reducing the craving for tobacco smoking - 500-1000 mg 3 times a day for 5-6 weeks.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
55FE6NPG89
Record Status Validated (UNII)
Record Version